<scp>MELD</scp> 3.0 Improves Risk Stratification and Mortality Prediction in Hepatorenal Syndrome‐Acute Kidney Injury: A Multicentre Study
This is the first large-scale study to validate MELD 3.0 in HRS-AKI. By offering enhanced discrimination and clinically meaningful reclassification, MELD 3.0 provides a more refined tool for early risk stratification, with potential to guide timely intervention, inform transplant decisions and improve personalized care in this critically ill population.
Authors
- Jing Ma (ORCID: https://orcid.org/0000-0001-8925-7686)
- Guang‐Hong Yang (ORCID: https://orcid.org/0000-0002-8911-0112)
- Qin Zhou (ORCID: https://orcid.org/0000-0002-7205-082X)
- Jiong Yu
- Haijun Huang (ORCID: https://orcid.org/0000-0002-2591-8729)
- Xinyi Chen (ORCID: https://orcid.org/0000-0002-6990-5233)
- Lanjuan Li (ORCID: https://orcid.org/0000-0001-6945-0593)
- Rui Luo (ORCID: https://orcid.org/0009-0001-3711-6643)
- Hongcui Cao
- Tan Li (ORCID: https://orcid.org/0000-0002-4480-5674)
- Jingyi Chen (ORCID: https://orcid.org/0000-0002-3476-1540)
- Xiaoxiao Chen (ORCID: https://orcid.org/0000-0003-3907-8465)
- Xiaoqing Lu
- Qiaoling Pan (ORCID: https://orcid.org/0000-0002-3771-8193)
- Chenjie Huang
Institutions
- Zhejiang Chinese Medical University (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- Zhejiang Provincial People's Hospital (CN)
- Hangzhou Medical College (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2025-07-04
- DOI
- https://doi.org/10.1111/apt.70265
- Citations
- 1
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities